Eyebot gets $ 20 million in the A series to enhance the expansion of access to the eyes

EyebotAn young company that provides a 90 -second vision test that offers glasses prescribed for the doctor, received $ 20 million of funding from the A.

The Boston -based Startup, founded in 2021, simplifies how people reach vision care by eliminating traditional obstacles, such as appointments delays, limited access, complex insurance requirements, and cost.

Her kiosks, already in shopping centers, universities, retail shops, pharmacies, grocery chains, schools, and airports, provides a free vision test for 90 seconds. According to the company, each prescription test is born reviewed and approved by licensed ophthalmologists, guaranteeing fast, comfortable and reliable prescriptions.

The new financing, which brings the total Eyebot financing to more than $ 30 million, comes about a year after the start of the start A round seed was raised in June 2024. Since then, the startup company has conducted more than 45,000 Free Vision tests on the right track to provide more than half a million annually, she says.

“Since our seed tour, this shift has been exciting. We have moved from experience to partnership with some of the largest companies in the United States, launching stalls throughout the country, and connecting tens of thousands of vision tests,” said Matthias Hoffman, co -founder of Techcrunch. “The revenues expand and double our team.

Hoffman said that what distinguishes Eyebot from each other is a mixture of rest and medical guarantee. Each test is reviewed by the doctor, and all prescriptions are released under a clinical supervision. If the test results indicate anything unusual, patients are referred to comprehensive personnel tests. He says that the speed balance in addition to clinical supervision earns confidence.

Hoffman said: “On our shopping centers sites, we saw a sudden absorption of parents with children,” Hoffman said. “They will stop between the stores, try Eyebot – sometimes even while carrying the hands of their children – and leave a prescription in just a few minutes.”

Convincing providers have proven to adopt the technology approach in difficulty. Doubts were deeply early: Doctors worried about accuracy, while patients wondered whether it was a speed that could be reliable, according to Huffan. He says that the frequency is reduced as soon as the service providers teach that the experiment does the doctors review each result, which many enjoy more than a decade of experience.

Eyebot in the early stages of marketing. The free vision test is provided to consumers, and if a prescription is needed, then one of the company’s doctors verifies this for a fee. In addition, the company rents its kiosks for visual retailers, glasses of glasses, and independent practices.

Through the series A, the company plans to expand the scope of publishing a booth and expanding its team via products, clinical operations and commercial growth.

The last round was led by General Combunst and included the participation of returning investors, ALYCORP, Baukunst, Village Global, Humba Venture, Ravelin and Ubiquity Ventures.